-
RNA Targeting Small Molecule Drug Discovery Market Size, Share, Revenue, Trends And Drivers For 2024-2033
13 May 2024 14:00 GMT
… drug discovery market is due to the increasing prevalence of cancer, genetic … RNA Aptamers, Small Interfering RNA (siRNA), Ribozymes, Other Technologies
• By … for treating various diseases, including genetic disorders, viral infections, neurodegenerative …
-
Advancing The Future Of Medicine By Getting Back To Its Genetic Roots
09 May 2024 23:01 GMT
… , and genetic medicines are beginning to flip the drug industry inside … support a growing portfolio of genetic medicines:
siRNA Technology: leveraging technologies like … in 2023 we acquired Decibel Therapeutics, cementing a long-standing collaboration …
-
FDA grants breakthrough therapy designation to myotonic dystrophy type 1 drug
09 May 2024 19:20 GMT
… receptor 1 along with a siRNA which specifically targets DMPK.
AOC … had previously been granted orphan drug and fast track designations by …
-
N4 Pharma announces collaboration with SRI to target and treat previously unreachable cells in the human body
09 May 2024 09:27 GMT
… , and nucleic acids (including siRNA, ASOs, and DNA) to … and therefore, untreatable.
N4 Pharma’s silica nanoparticle Nuvec has … future-proof inhaled drug delivery
Kindeva Drug Delivery acquires Summit … from small and virtual biotechnology companies to top 10 …
-
FDA Grants Orphan Drug Designation to Biompharma’s Bi104, a microbiome-modifying biologic, for the treatment of Angelman Syndrome
08 May 2024 13:25 GMT
… that Bi104, its innovative drug product, has been granted … #39;s disease. BIOM Pharma formulated Bi104 as a microbiome … drug development is in progress with gene therapy and siRNA- … groundbreaking work in rare disease therapeutics, please visit https:/…
-
Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business Update
09 May 2024 20:05 GMT
… preferred next-generation intracellular oral drug delivery platform, potentially facilitating a … oligonucleotides such as ASOs and siRNA. The combination of its unique … next-generation orally available intracellular drug delivery platform. For more information …
-
Wave Life Sciences Announces Appointment of Dr. Erik Ingelsson as Chief Scientific Officer
09 May 2024 11:00 GMT
… : WVE), a clinical-stage biotechnology company focused on unlocking the … , including RNA editing and siRNA.” While at GSK, Dr … cellular sciences to drive drug discovery and development. His … RNA therapeutics platform and its people to rapidly translate genetic …
-
LncRNA-Snhg3 Aggravates Hepatic Steatosis by Regulating PPARγ via SND1/H3K27me3
13 May 2024 15:03 GMT
… . Multifarious factors such as genetic and epigenetic factors, nutritional … of SND1 was disrupted with siRNA (up, western blotting; down … of mRNA or producing endogenous siRNA; (4) regulating the … (JM-02862M1, Beijing BioDee Biotechnology Co., Ltd.). All animal …
-
Combined ROS Sensitive Folate Receptor Targeted Micellar Formulations of Curcumin Effective Against Rheumatoid Arthritis in Rat Model
13 May 2024 08:47 GMT
… -based nanomedicine therapeutics for rheumatoid arthritis. Crit Rev Ther Drug Carrier Syst … thioketal nanoparticles loaded with TNF-α-siRNA target inflammation and inhibit gene … osteoclastogenesis in rheumatoid arthritis. 3 Biotech. 2021;11(10):436. doi …
-
Wave Life Sciences Ltd. (NASDAQ:WVE) Q1 2024 Earnings Call Transcript
10 May 2024 20:54 GMT
… strategy, including growing our genetics and genomics capability for … discover and validate novel drug targets and accelerate the … with multiple approved silencing therapeutics on the market. GalNAc … obesity therapeutic. Using GalNAc-siRNA silencing, we aim to …